Does Ozempic cause stomach paralysis? What the data shows

What did @newsnationnow actually say?

Emily Wright told Chris Cuomo she developed what sounds like gastroparesis after a year on Ozempic, saying "nobody told me that Ozempic could cause gastroparesis" before starting the medication. She described escalating symptoms, hospitalization, and having to quit her job. She also said there's "no research to know when I'm going to get better." This is a personal account, not a scientific claim, and that distinction matters a lot for how we evaluate it.

Wright's experience is real and serious. But the video frames her story in a way that implies gastroparesis is a hidden, undisclosed risk, which is worth examining carefully. Her account also makes a factual claim worth checking: that no information was given about this risk and that no research exists on her prognosis.

Does the science back this up?

The gastroparesis link is real, but the "nobody told me" framing is complicated. GLP-1 receptor agonists slow gastric emptying by design, and that mechanism is well-documented. The question is whether that delayed emptying crosses into clinical gastroparesis, which is a distinct, serious condition.

A 2023 study published in JAMA by Sodhi et al. found that GLP-1 receptor agonist users had a significantly higher risk of gastroparesis compared to users of other weight-loss medications, with an adjusted hazard ratio of 9.09. That is not a small signal. The study used insurance claims data and had real limitations, but the association is hard to dismiss. Semaglutide's prescribing information does list delayed gastric emptying and nausea as known effects, though "gastroparesis" as a clinical diagnosis is not prominently featured in the standard patient-facing materials. So there is a gap between what the mechanism implies and what patients are routinely told.

What did they get wrong (or right)?

Wright gets credit for accurately describing a documented pharmacological risk. The Sodhi et al. finding was significant enough that the FDA added a warning to GLP-1 labels in 2024 specifically about ileus and severe gastrointestinal events. She is not making this up, and dismissing her experience as rare or anomalous is not supported by the emerging data.

Where she overshoots is the claim that there is "no research" on her prognosis. That is not accurate. Gastroparesis prognosis research exists, including long-term outcome data from the NIH Gastroparesis Clinical Research Consortium. Recovery is variable and often slow, but physicians have frameworks for management. Her doctors may not have had clear answers for her specifically, which is understandable, but that is different from saying no research exists. The "no research" framing is an overstatement that could unnecessarily alarm people currently on GLP-1 therapy.

What should you actually know?

GLP-1 drugs slow gastric emptying as part of how they work. For most people, this causes temporary nausea or discomfort that fades. For a smaller group, it appears to tip into something more serious. The Sodhi et al. 2023 JAMA study put a real number on that risk for the first time, and the FDA responded. That is the regulatory system working, slowly, but working.

If you are taking semaglutide or any GLP-1 medication and you are experiencing persistent vomiting, severe nausea, or feeling full after eating almost nothing, those symptoms warrant a conversation with your prescriber. Not a pause, not a panic, a conversation. Gastroparesis is diagnosable and manageable, even if it is not quickly reversible in all cases.

• The risk appears real and the FDA has updated labeling accordingly as of 2024.
• Most patients do not develop clinical gastroparesis, but "most" is not "all."
• Symptoms that do not resolve after dose adjustment should be investigated, not waited out indefinitely.
• Novo Nordisk's statement that side effects are "mild to moderate" for most patients is accurate as a population-level description and inadequate as informed consent for any individual patient.